Rallybio CorpRLYBEarnings & Financial Report
Rallybio Corp is a clinical-stage biotechnology company dedicated to developing transformative therapies for patients with severe, rare diseases with high unmet medical needs. Its core development pipeline targets hematologic disorders, fetal and neonatal hemolytic disease, and complement-mediated conditions, serving patient populations primarily in North America and Europe.
Revenue
$299.0K
Gross Profit
N/A
Operating Profit
$-12.1M
Net Profit
$-11.5M
Gross Margin
N/A
Operating Margin
-4035.5%
Net Margin
-3834.8%
YoY Growth
N/A
EPS
$-0.26
Rallybio Corp Q3 FY2024 Financial Summary
Rallybio Corp reported revenue of $299.0K for Q3 FY2024, with a net profit of $-11.5M (up 37.6% YoY) (-3834.8% margin).
Key Financial Metrics
| Total Revenue | $299.0K |
|---|---|
| Net Profit | $-11.5M |
| Gross Margin | N/A |
| Operating Margin | -4035.5% |
| Report Period | Q3 FY2024 |
Rallybio Corp Annual Revenue by Year
Rallybio Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $858.0K).
| Year | Annual Revenue |
|---|---|
| 2025 | $858.0K |
| 2024 | $636.0K |
Rallybio Corp Quarterly Revenue & Net Profit History
Rallybio Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $222.0K | +484.2% | $-5.9M | -2636.0% |
| Q3 FY2025 | $212.0K | -29.1% | $16.0M | 7554.7% |
| Q2 FY2025 | $212.0K | -29.1% | $-9.7M | -4576.9% |
| Q1 FY2025 | $212.0K | — | $-9.4M | -4452.4% |
| Q4 FY2024 | $38.0K | — | $-11.0M | -29063.2% |
| Q3 FY2024 | $299.0K | — | $-11.5M | -3834.8% |
| Q2 FY2024 | $299.0K | — | $-16.2M | -5430.1% |
| Q1 FY2024 | $0 | — | $-19.0M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $299000 | $299000 | $38000 | $212000 | $212000 | $212000 | $222000 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | -29.1% | -29.1% | 484.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $99.4M | $92.4M | $79.0M | $68.1M | $58.0M | $51.0M | $67.7M | $62.3M |
| Liabilities | $10.2M | $12.4M | $8.2M | $6.5M | $3.9M | $5.0M | $4.6M | $4.3M |
| Equity | $89.2M | $80.0M | $70.8M | $61.7M | $54.1M | $46.0M | $63.0M | $58.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-15.5M | $-10.4M | $-13.5M | $-9.9M | $-10.2M | $-8.4M | $-6.5M | $-4.7M |